Poster: SITC 2022 – 37th annual SITC meeting – Nov 8-12 2022, Boston, MA
Poster | April 19, 2022
ACTM-838, a Microbial-based Immunotherapy That Enriches in Solid Tumors After IV Dosing, Reverses the Immunosuppressive TME to Promote Durable Anti-tumor Immunity, Alone and in Combination with Anti-PD1 in Mice
